Showing 1 to 12 of 168 results
Weight Stigma: Counterproductive to Weight Loss and Harmful to Mental Health
Research reveals that weight stigma, a pervasive misconception that weight is entirely self-controlled, is counterproductive to weight loss and harms mental health by increasing risks of depression, anxiety, and disordered eating; those with less stigma were more likely to maintain weight loss after...
Weight Stigma: Counterproductive to Weight Loss and Harmful to Mental Health
Research reveals that weight stigma, a pervasive misconception that weight is entirely self-controlled, is counterproductive to weight loss and harms mental health by increasing risks of depression, anxiety, and disordered eating; those with less stigma were more likely to maintain weight loss after...
Progress
20% Bias Score
15 Million Undiagnosed Cases of Aggressive Fatty Liver Disease in US and Europe
Research reveals that over 15 million people in the US, UK, Germany, and France are undiagnosed with metabolic dysfunction-associated steatohepatitis (MASH), the most aggressive form of fatty liver disease, resulting in significant economic and health consequences; improved screening, treatment, and...
15 Million Undiagnosed Cases of Aggressive Fatty Liver Disease in US and Europe
Research reveals that over 15 million people in the US, UK, Germany, and France are undiagnosed with metabolic dysfunction-associated steatohepatitis (MASH), the most aggressive form of fatty liver disease, resulting in significant economic and health consequences; improved screening, treatment, and...
Progress
40% Bias Score
Wegovy Use Among Teens Increases by 50% in 2024
Data shows a 50% increase in Wegovy prescriptions for American teens in 2024, reaching 14.8 per 100,000 adolescents, despite concerns about long-term effects and limited insurance coverage; this follows a strong recommendation from the American Academy of Pediatrics in January 2023.
Wegovy Use Among Teens Increases by 50% in 2024
Data shows a 50% increase in Wegovy prescriptions for American teens in 2024, reaching 14.8 per 100,000 adolescents, despite concerns about long-term effects and limited insurance coverage; this follows a strong recommendation from the American Academy of Pediatrics in January 2023.
Progress
36% Bias Score
China Combats Childhood Obesity with Fitness Initiatives
China is tackling rising childhood obesity (nearly 19 percent of children aged 6-17 are overweight or obese) with a national weight management campaign, increased school physical education, and the growing popularity of children's fitness events like the Spartan Kids race.
China Combats Childhood Obesity with Fitness Initiatives
China is tackling rising childhood obesity (nearly 19 percent of children aged 6-17 are overweight or obese) with a national weight management campaign, increased school physical education, and the growing popularity of children's fitness events like the Spartan Kids race.
Progress
28% Bias Score
Proposed Australian Sugar Tax: \$1.4 Billion Revenue, Health Debate
A Labor MP proposes a 20% tax on sugary drinks in Australia, aiming to raise \$1.4 billion in revenue and reduce sugar content in beverages, while facing opposition due to concerns about its effect on low-income earners and effectiveness in combating obesity.
Proposed Australian Sugar Tax: \$1.4 Billion Revenue, Health Debate
A Labor MP proposes a 20% tax on sugary drinks in Australia, aiming to raise \$1.4 billion in revenue and reduce sugar content in beverages, while facing opposition due to concerns about its effect on low-income earners and effectiveness in combating obesity.
Progress
36% Bias Score
France Expands Access to Anti-Obesity Drugs
The French government will allow general practitioners to prescribe Wegovy and Mounjaro to combat obesity, affecting nearly 50% of French adults; a plan launching in September will address this through education, healthcare, sports, and medication, aiming to curb cardiovascular deaths.
France Expands Access to Anti-Obesity Drugs
The French government will allow general practitioners to prescribe Wegovy and Mounjaro to combat obesity, affecting nearly 50% of French adults; a plan launching in September will address this through education, healthcare, sports, and medication, aiming to curb cardiovascular deaths.
Progress
40% Bias Score
China Expands TCM Pediatric Services to Combat Childhood Obesity
China will require all tertiary and at least 80 percent of secondary public traditional Chinese medicine hospitals to establish pediatric departments by November 2024, expanding access to TCM pediatric care and addressing rising childhood obesity rates.
China Expands TCM Pediatric Services to Combat Childhood Obesity
China will require all tertiary and at least 80 percent of secondary public traditional Chinese medicine hospitals to establish pediatric departments by November 2024, expanding access to TCM pediatric care and addressing rising childhood obesity rates.
Progress
32% Bias Score
Ozempic Weight Loss Drugs Linked to Increased Kidney Cancer Risk
A major study of 86,000 patients revealed that while weight-loss drugs like Ozempic lower the risk of 16 cancers by 17 percent, they may increase kidney cancer risk by 33 percent, prompting calls for further research.
Ozempic Weight Loss Drugs Linked to Increased Kidney Cancer Risk
A major study of 86,000 patients revealed that while weight-loss drugs like Ozempic lower the risk of 16 cancers by 17 percent, they may increase kidney cancer risk by 33 percent, prompting calls for further research.
Progress
60% Bias Score
UK Obesity Crisis: Weight-Loss Drug Success Creates Dangerous Black Market
In the UK, the rising popularity of GLP-1 weight-loss medication like Wegovy and Ozempic, despite strict NHS access, has created a black market with reports of misuse leading to hospitalizations; while effective for weight loss and related health problems, unregulated access poses serious health ris...
UK Obesity Crisis: Weight-Loss Drug Success Creates Dangerous Black Market
In the UK, the rising popularity of GLP-1 weight-loss medication like Wegovy and Ozempic, despite strict NHS access, has created a black market with reports of misuse leading to hospitalizations; while effective for weight loss and related health problems, unregulated access poses serious health ris...
Progress
44% Bias Score
High Visceral Fat Poses Significant Health Risks for Men
High visceral fat in men, often hidden by muscle or societal acceptance, increases mortality risk; 40-46% of US men are obese, and new medications offer potential solutions, but require further study and a holistic approach.
High Visceral Fat Poses Significant Health Risks for Men
High visceral fat in men, often hidden by muscle or societal acceptance, increases mortality risk; 40-46% of US men are obese, and new medications offer potential solutions, but require further study and a holistic approach.
Progress
72% Bias Score
Tirzepatide Shows Superior Weight Loss Compared to Semaglutide in Clinical Trial
A new study comparing tirzepatide and semaglutide in 751 obese participants found tirzepatide produced significantly greater weight loss (average 50 pounds, 20.2% body weight) versus semaglutide (average 33 pounds, 13.7%), attributed to its dual hormone action; however, the study's open-label design...
Tirzepatide Shows Superior Weight Loss Compared to Semaglutide in Clinical Trial
A new study comparing tirzepatide and semaglutide in 751 obese participants found tirzepatide produced significantly greater weight loss (average 50 pounds, 20.2% body weight) versus semaglutide (average 33 pounds, 13.7%), attributed to its dual hormone action; however, the study's open-label design...
Progress
52% Bias Score
GLP-1 Agonists Show Potential for Reducing Obesity-Related Cancer Risk
A new study of 170,030 obese and diabetic adults in the US found that GLP-1 receptor agonists (Ozempic, Wegovy, etc.) may modestly reduce the risk of 14 obesity-related cancers and all-cause mortality, especially in women, compared to DDP-4 inhibitors.
GLP-1 Agonists Show Potential for Reducing Obesity-Related Cancer Risk
A new study of 170,030 obese and diabetic adults in the US found that GLP-1 receptor agonists (Ozempic, Wegovy, etc.) may modestly reduce the risk of 14 obesity-related cancers and all-cause mortality, especially in women, compared to DDP-4 inhibitors.
Progress
44% Bias Score
Showing 1 to 12 of 168 results